The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Safety and tolerability of omalizumab
Abstract
Summary: Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent allergic (IgE‐mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post‐marketing safety data. Analysis focuses on the risk of immune‐system effects, hypersensitivity reactions, malignant neoplasia, parasitic infections and thrombocytopenia. Results Omalizumab exhibited a good safety and tolerability profile that was maintained up to 4 years in one study. The incidence of anaphylaxis was 0.14% in omalizumab‐treated patients and 0.07% in control patients. No omalizumab‐treated patient developed measurable anti‐omalizumab antibodies. Post‐marketing, based on estimated exposure of 57 300 patients (June 2003–December 2006), the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients. Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab. Conclusion Data indicate that the proven efficacy of add‐on omalizumab in patients with moderate‐to‐severe or severe allergic asthma is accompanied by a favourable safety and tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Kuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., Leupold, W., Bergmann, K.-C., Rolinck-Werninghaus, C., Gräve, M., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121949 · Cited by 342
Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.032 · Cited by 295
Limb, S. L., Starke, P. R., Lee, C. E., & Chowdhury, B. A. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.022 · Cited by 170
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
Self-citationExploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Metadata
- Authors
- Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2009-05-11
- Volume
- 39
- Issue
- 6
- Pages
- 788-797
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2137404654
- Cited by
- 252
- References
- 4
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of omalizumab. https://app.cochat.ai/papers/10.1111/j.1365-2222.2009.03214.x
- The paper
- Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P. (2009). Safety and tolerability of omalizumab. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2009.03214.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.